170,532 Shares in BioAge Labs, Inc. $BIOA Bought by Yiheng Capital Management L.P.

Key Points

• Yiheng Capital Management purchased 170,532 BioAge Labs shares worth approximately $4.18 million, giving it a 0.37% stake and making BIOA its 16th-largest holding.
• Analyst sentiment remains mostly positive, with six Buy ratings and one Sell rating; the consensus is “Moderate Buy” with an average price target of $36.57.
• BioAge reported a quarterly loss of $0.58 per share, better than the expected $0.65 loss, alongside $2.45 million in revenue. Despite the earnings beat, the stock opened at $9.65, well below its 12-month high of $25.95.

Yiheng Capital Management L.P. purchased a new stake in BioAge Labs, Inc. (NASDAQ:BIOA - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 170,532 shares of the company's stock, valued at approximately $4,180,000. BioAge Labs makes up about 1.4% of Yiheng Capital Management L.P.'s holdings, making the stock its 16th largest position. Yiheng Capital Management L.P. owned about 0.37% of BioAge Labs as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in shares of BioAge Labs during the 2nd quarter worth about $84,000. CWM LLC increased its stake in BioAge Labs by 39.9% in the fourth quarter. CWM LLC now owns 3,693 shares of the company's stock valued at $49,000 after purchasing an additional 1,053 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in BioAge Labs during the third quarter worth approximately $27,000. State of Wyoming acquired a new stake in BioAge Labs during the 2nd quarter worth $154,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in BioAge Labs during the 2nd quarter worth $234,000.

Analysts Set New Price Targets

Several research firms have issued reports on BIOA. BTIG Research restated a "buy" rating and issued a $40.00 price objective on shares of BioAge Labs in a research note on Monday, August 3rd. Roth Capital reissued a "buy" rating and issued a $25.00 target price on shares of BioAge Labs in a report on Friday, July 31st. Weiss Ratings reissued a "sell (d-)" rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Needham & Company LLC cut their price target on BioAge Labs from $50.00 to $35.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. Finally, Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a research note on Friday, July 31st. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $36.57.

BioAge Labs Stock Performance

Shares of BIOA stock opened at $9.65 on Monday. The company has a market capitalization of $442.94 million, a P/E ratio of -4.05 and a beta of 0.94. The business's 50 day moving average is $17.80 and its two-hundred day moving average is $18.17. BioAge Labs, Inc. has a twelve month low of $4.55 and a twelve month high of $25.95.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The firm had revenue of $2.45 million for the quarter. As a group, equities analysts predict that BioAge Labs, Inc. will post -2.45 earnings per share for the current fiscal year.

BioAge Labs Company Profile

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.